Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2010

Conditions
Non-Hodgkin's LymphomaMantle Cell Lymphoma
Interventions
DRUG

Bendamustine plus Rituximab

Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles

DRUG

Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w

Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles

Trial Locations (1)

35392

StiL Head Office; Justus-Liebig-University, Giessen

All Listed Sponsors
lead

University of Giessen

OTHER

NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | Biotech Hunter | Biotech Hunter